Metrizamide
(Synonyms: 甲泛葡胺,Amipaque) 目录号 : GC44187
A contrast reagent
Cas No.:31112-62-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Metrizamide is a non-ionic contrast agent.[1] In vivo, metrizamide (0.1 ml/kg of a 370 mg I/ml solution) does not induce EEG abnormalities, indicating minimal neurotoxicity in rabbits. It has also been used as a solute in gradient centrifugation applications.[2]
Reference:
[1]. Maly, P., Elmqvist, D., Almén, T., et al. Comparison between EEG and observation of rabbit behaviour in evaluation of subarachnoid neurotoxicity of metrizamide. Acta. Radiol. Diagn. (Stockh.) 27(2), 235*240 (1986).
[2]. Hsu, C.-H., Di Carlo, D., Chen, C., et al. Microvortex for focusing, guiding and sorting of particles. Lab Chip. 8(12), 2128-2134 (2008).
| Cas No. | 31112-62-6 | SDF | |
| 别名 | 甲泛葡胺,Amipaque | ||
| 化学名 | 2-[[3-(acetylamino)-5-(acetylmethylamino)-2,4,6-triiodobenzoyl]amino]-2-deoxy-D-glucose | ||
| Canonical SMILES | IC1=C(C(N[C@@H](C=O)[C@H]([C@H](O)[C@H](O)CO)O)=O)C(I)=C(NC(C)=O)C(I)=C1N(C)C(C)=O | ||
| 分子式 | C18H22I3N3O8 | 分子量 | 789.1 |
| 溶解度 | DMSO : ≥ 50 mg/mL (63.36 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.2673 mL | 6.3363 mL | 12.6727 mL |
| 5 mM | 0.2535 mL | 1.2673 mL | 2.5345 mL |
| 10 mM | 0.1267 mL | 0.6336 mL | 1.2673 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Explanation of Metrizamide brain penetration: a review
J Comput Assist Tomogr 1980 Apr;4(2):191-3.PMID:6988475DOI:10.1097/00004728-198004000-00011.
The penetration of intrathecally injected Metrizamide into brain and spinal cord substance is a phenomenon that has surprised and puzzled radiologists. No suitable explanation has been offered in the radiologic literature. This article reviews the recent literature on the relationship between the cerebrospinal fluid (CSF) space and the extracellular fluid (ECF) space of the brain. Recent evidence has shown that these spaces are in fact one compartment with no diffusion barrier between them. Thus, penetration of Metrizamide into the brain is an expected rather than surprising phenomenon. An explanation is offered as to why Metrizamide does not penetrate edematous or infarcted portions of brain on the basis of a pressure gradient between damaged brain ECF and CSF spaces.
Metrizamide meningitis
South Med J 1984 Jan;77(1):88-9.PMID:6695228DOI:10.1097/00007611-198401000-00026.
A 39-year-old man had fever, nuchal rigidity, vomiting, and mental confusion within 24 hours after myelography with Metrizamide, a water-soluble contrast medium. Cloudy cerebrospinal fluid showing pleocytosis, a significantly elevated level of protein, and a low glucose value suggested septic meningitis, but rapid resolution of signs of meningeal irritation and negative spinal fluid cultures made chemical meningitis due to the Metrizamide the likely diagnosis.
Metrizamide: a review with emphasis on drug interactions
Am J Hosp Pharm 1980 Apr;37(4):510-3.PMID:6103672doi
The pharmacology, side effects, and possible drug interactions of Metrizamide, a water-solulbe contrast medium for myelography, are reviewed. Metrizamide concentration in the brain reaches maximal levels two to six hour after lumbar injection, depending on dose and patient positioning, and is largely (55-96%) excreted from the body after 24 hours. Its lower neurotoxicity, compared with other water-soluble contrast agents, can be attributed in part to its undissociated, non-ionic nature. Common side effects, which include headache, nausea, and vomiting, occur to the same degree as with other myelographic contrast media. Reported data suggest that convulsions, which have occurred in a very small percentage of patients, are related to the amount of contrast medium reaching the brain which, in turn, is largely a factor of dose and examination technique. Although the risk of seizures is small, it is recommended that drugs that lower the seizure threshold (phenothiazine derivatives, butyrophenones, tricyclic antidepressants, and MAO-inhibitors) should be avoided 48 hours before Metrizamide administration (if possible), should not be used to control nausea, and should not be resumed for 24 to 48 hours after the myelographic procedure. The value of premedication (e.g., with diazepam) to prevent seizures has not been established and is not recommended.
Metrizamide myelography
AJR Am J Roentgenol 1977 Sep;129(3):481-4.PMID:409203DOI:10.2214/ajr.129.3.481.
Complete myelography using Metrizamide and a lumbar puncture is described with special emphasis on the cervical region. Good visualization of the cervical region was obtained in 19 of 20 patients using 10-12 ml and iodine concentrations of 250 mg/ml without special techniques or precautions. Possible explanations of failure to visualize the complete subarachnoid space are discussed.
Metrizamide in cervical myelography. Survey and present state
Acta Radiol Suppl 1977;355:85-97.PMID:400908doi
The total number of patients examined with Metrizamide (Amipaque) for cervical myelography up to 31 December 1976, exceeds 2,000. Review of this series under more detailed analysis of the 365 examinations performed at the Ullevål Sykehus indicate that such examinations can be performed safely and with excellent diagnostic results, provided the technique is satisfactory. Various techniques may be adequate. The injection of the contrast medium via a lateral C1-C2 puncture with the patient prone ensures optimum control of the contrast column to avoid intracranial flow, and therefore to give the lowest rate of side effects.